Blythe Thomson

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology · 2018 · 614 citations

Medicine, Oncology, Pharmacology +12

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Eytan M. Stein, Guillermo Garcia‐Manero, David A. Rizzieri et al. · Blood · 2018 · 457 citations · Full text

Life Sciences, Molecular Biology, Oncology +10

Anti–interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes

Jennifer K. Garrett, Sean C. Jameson, Blythe Thomson et al. · Journal of Allergy and Clinical Immunology · 2004 · 364 citations · Full text

Life Sciences, Immunology, Pharmacology +14

Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation

Blythe Thomson, Kent A. Robertson, Darla Gowan et al. · Blood · 2000 · 233 citations

Life Sciences, Hematology, Immunology +16

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

Yousif Matloub, Bruce Bostrom, Stephen P. Hunger et al. · Blood · 2011 · 148 citations · Full text

Medicine, Oncology, Pediatrics +11